According to Tufts Center for the Study of Drug Development (Tufts CSDD) the number of monoclonal antibody products in development nearly tripled in the last decade. A recent Tufts CSDD study found that monoclonal antibody products, referred to as mAbs, require an average of 7.6 years to complete the clinical development cycle and gain marketing approval. Development and approval times for mAbs fared well as compared with small molecule drugs, which require an average of 7.5 years. According to ...